Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Inclusion criteria

• 18 years of age or older
• Diagnosis of open angle glaucoma or ocular hypertension in both eyes
• Post-washout intraocular pressure >20mmHg and <30mmHg in 1 or both eyes at 2 qualification visits
• Corrected visual acuity equivalent to 20/200
• Able to give informed consent and follow study instructions

Exclusion criteria

• Clinically significant ocular disease
• Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles
• Unmedicated intraocular pressure ≥30mmHg
• Use of more than 2 ocular hypotensive medications within 30 days of screening
• Known hypersensitivity to any component of the formulation
• Previous glaucoma surgery or refractive surgery
• Ocular trauma within 6 months prior to screening
• Any ocular surgery or non-refractive laser treatment within 3 months prior to screening
• Recent or current ocular infection or inflammation in either eye
• Used ocular medication in either eye of any kind within 30 days of screening
• Mean central corneal thickness >620µm at screening
• Any abnormality preventing reliable applanation tonometry of either eye
• Clinically significant abnormalities in lab tests at screening
• Known hypersensitivity or contraindication to beta-adrenoceptor antagonists
• Clinically significant systemic disease
• Participation in any investigational study within 60 days prior to screening
• Used any systemic medication that could have a substantial effect in intraocular pressure within 30 days prior to screening
• Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control